New insights into the role of inflammation in the pathogenesis of atherosclerosis

International Journal of Molecular Sciences

Volumn 18, Issue 10, 2017, Pages

  Wu, Meng Yu ^a,b   Li, Chia Jung ^c   Hou, Ming Feng ^d,e,f   Chu, Pei Yi ^c,g,h  

^a TAIPEI TZU CHI HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^h NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Atherosclerosis; Atherosclerotic immunity; Atherosclerotic microenvironment; Macrophage; Oxidative stress

Indexed keywords

ENDOTHELIN 1; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR; TRIACYLGLYCEROL;

ANTIGEN PRESENTING CELL; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL TONE; CD8+ T LYMPHOCYTE; CELL DAMAGE; DENDRITIC CELL; DISEASE COURSE; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY CELL; LIPID METABOLISM; LIPID STORAGE; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MAST CELL; MICROENVIRONMENT; OXIDATIVE STRESS; REVIEW; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; ANIMAL; CELL PROLIFERATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CELL PROLIFERATION; HUMANS; INFLAMMATION; MACROPHAGES; OXIDATIVE STRESS;

EID: 85030100079     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18102034     Document Type: Review

References (154)

1. Falk, E. Pathogenesis of Atherosclerosis. J. Am. Coll. Cardiol. 2006, 47, C7-C12.
2. Singh, B.R.; Mengi, S.A.; Xu, Y.J.; Arneja, A.S.; Dhalla, N.S. Pathogenesis of Atherosclerosis: A Multifactorial Process. Exp. Clin. Cardiol. 2002, 7, 40-53.
3. Albertini, R.; Moratti, R.; de Luca, G. Oxidation of Low-Density Lipoprotein in Atherosclerosis from Basic Biochemistry to Clinical Studies. Curr. Mol. Med. 2002, 2, 579-592.
4. Nguyen, P.; Leray, V.; Diez, M.; Serisier, S.; le Bloc’h, J.; Siliart, B.; Dumon, H. Liver Lipid Metabolism. J. Anim. Physiol. Anim. Nutr. 2008, 92, 272-283.
5. Khalil, F.M.; Wagner, W.D.; Goldberg, I.J. Molecular Interactions Leading to Lipoprotein Retention and the Initiation of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 2211-2218.
6. Kramer-Guth, A.; Greiber, S.; Pavenstadt, H.; Quaschning, T.; Winkler, K.; Schollmeyer, P.; Wanner, C. Interaction of Native and Oxidized Lipoprotein(a) with Human Mesangial Cells and Matrix. Kidney Int. 1996, 49, 1250-1261.
7. Williams, K.J. Arterial Wall Chondroitin Sulfate Proteoglycans: Diverse Molecules with Distinct Roles in Lipoprotein Retention and Atherogenesis. Curr. Opin. Lipidol. 2001, 12, 477-487.
8. Wiśniewska, A.; Olszanecki, R.; Totoń-Żurańska, J.; Kuś, K.; Stachowicz, A.; Suski, M.; Gębska, A.; Gajda, M.; Jawień, J.; Korbut, R. Anti-Atherosclerotic Action of Agmatine in ApoE-Knockout Mice. Int. J. Mol. Sci. 2017, 18, 1706.
9. Choi, H.S.; Harkewicz, R.; Lee, J.H.; Boullier, A.; Almazan, F.; Li, A.C.; Witztum, J.L.; Bae, Y.S.; Miller, Y.I. Lipoprotein Accumulation in Macrophages Via Toll-Like Receptor-4-Dependent Fluid Phase Uptake. Circ. Res.2009, 104, 1355-1363.
10. Zhou, S.M.; Chadipiralla, K.; Mendez, A.J.; Jaimes, E.A.; Silverstein, R.L.; Webster, K.; Raij, L. Nicotine Potentiates Proatherogenic Effects of OxLDL by Stimulating and Upregulating Macrophage CD36 Signaling. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H563-H574.
11. Bloomer, R.J. Decreased Blood Antioxidant Capacity and Increased Lipid Peroxidation in Young Cigarette Smokers Compared to Nonsmokers: Impact of Dietary Intake. Nutr. J. 2007, 6, 39.
12. Frostegård, J.; Ruihua, W.U.; Lemne, C.; Thulin, T.; Witztum, J.L.; de Faire, U. Circulating Oxidized Low-Density Lipoprotein Is Increased in Hypertension. Clin. Sci. 2003, 105, 615-620.
13. Levitan, I.; Volkov, S.; Subbaiah, P.V. Oxidized Ldl: Diversity, Patterns of Recognition, and Pathophysiology. Antioxid. Redox. Signal. 2010, 13, 39-75.
14. Parthasarathy, S.; Raghavamenon, A.; Garelnabi, M.O.; Santanam, N. Oxidized Low-Density Lipoprotein. Methods Mol. Biol. 2010, 610, 403-417.
15. Badrnya, S.; Assinger, A.; Volf, I. Native High Density Lipoproteins (HDL) Interfere with Platelet Activation Induced by Oxidized Low Density Lipoproteins (OxLDL). Int. J. Mol. Sci. 2013, 14, 10107.
16. Cominacini, L.; Garbin, U.; Pasini, A.F.; Davoli, A.; Campagnola, M.; Contessi, G.B.; Pastorino, A.M.; Cascio, V.L. Antioxidants Inhibit the Expression of Intercellular Cell Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Induced by Oxidized LDL on Human Umbilical Vein Endothelial Cells. Free Radic. Biol. Med. 1997, 22, 117-127.
17. Frostegard, J.; Haegerstrand, A.; Gidlund, M.; Nilsson, J. Biologically Modified LDL Increases the Adhesive Properties of Endothelial Cells. Atherosclerosis 1991, 90, 119-126.
18. Quinn, M.T.; Parthasarathy, S.; Steinberg, D. Lysophosphatidylcholine: A Chemotactic Factor for Human Monocytes and Its Potential Role in Atherogenesis. Proc. Natl. Acad. Sci. USA 1988, 85, 2805-2809.
19. Barbieri, S.S.; Cavalca, V.; Eligini, S.; Brambilla, M.; Caiani, A.; Tremoli, E.; Colli, S. Apocynin Prevents Cyclooxygenase 2 Expression in Human Monocytes through Nadph Oxidase and Glutathione Redox-Dependent Mechanisms. Free Radic. Biol. Med. 2004, 37, 156-165.
20. Carr, A.C.; McCall, M.R.; Frei, B. Oxidation of LDL by Myeloperoxidase and Reactive Nitrogen Species: Reaction Pathways and Antioxidant Protection. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1716-1723.
21. Cyrus, T.; Witztum, J.L.; Rader, D.J.; Tangirala, R.; Fazio, S.; Linton, M.F.; Funk, C.D. Disruption of the 12/15-Lipoxygenase Gene Diminishes Atherosclerosis in Apo E-Deficient Mice. J. Clin. Investig. 1999, 103, 1597-1604.
22. Nagy, L.; Tontonoz, P.; Alvarez, J.G.; Chen, H.; Evans, R.M. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ. Cell 1998, 93, 229-240.
23. Park, Y.M. CD36 Modulates Migration of Mouse and Human Macrophages in Response to Oxidized LDL and May Contribute to Macrophage Trapping in the Arterial Intima. J. Clin. Investig. 2009, 119, 136-145.
24. Park, Y.M.; Drazba, J.A.; Vasanji, A.; Egelhoff, T.; Febbraio, M.; Silverstein, R.L. Oxidized LDL/CD36 Interaction Induces Loss of Cell Polarity and Inhibits Macrophage Locomotion. Mol. Biol. Cell 2012, 23, 3057-3068.
25. Hansson, G.K.; Robertson, A.K.; Soderberg-Naucler, C. Inflammation and Atherosclerosis. Annu. Rev. Pathol. 2006,1, 297-329.
26. Liao, F.; Andalibi, A.; deBeer, F.C.; Fogelman, A.M.; Lusis, A.J. Genetic Control of Inflammatory Gene Induction and NF-κB-Like Transcription Factor Activation in Response to an Atherogenic Diet in Mice. J. Clin. Investig. 1993,91, 2572-2579.
27. Kohno, M.; Yokokawa, K.; Yasunari, K.; Minami, M.; Kano, H.; Hanehira, T.; Yoshikawa, J. Induction by Lysophosphatidylcholine, a Major Phospholipid Component of Atherogenic Lipoproteins, of Human Coronary Artery Smooth Muscle Cell Migration. Circulation 1998, 98, 353-359.
28. Lindner, V.; Lappi, D.A.; Baird, A.; Majack, R.A.; Reidy, M.A. Role of Basic Fibroblast Growth Factor in Vascular Lesion Formation. Circ. Res. 1991, 68, 106-113.
29. Stiko-Rahm, A.; Hultgardh-Nilsson, A.; Regnstrom, J.; Hamsten, A.; Nilsson, J. Native and Oxidized LDL Enhances Production of PDGF AA and the Surface Expression of PDGF Receptors in Cultured Human Smooth Muscle Cells. Arterioscler. Thromb. 1992, 12, 1099-1109.
30. Maiolino, G.; Rossitto, G.; Caielli, P.; Bisogni, V.; Rossi, G.P.; Cala, L.A. The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts. Mediat. Inflamm. 2013, 2013, 13.
31. Loidl, A.; Claus, R.; Ingolic, E.; Deigner, H.P.; Hermetter, A. Role of Ceramide in Activation of Stress-Associated MAP Kinases by Minimally Modified LDL in Vascular Smooth Muscle Cells. Biochim. Biophys. Acta 2004, 1690, 150-158.
32. Rajavashisth, T.B.; Liao, J.K.; Galis, Z.S.; Tripathi, S.; Laufs, U.; Tripathi, J.; Chai, N.N.; Xu, X.P.; Jovinge, S.; Shah, P.K. et al. Inflammatory Cytokines and Oxidized Low Density Lipoproteins Increase Endothelial Cell Expression of Membrane Type 1-Matrix Metalloproteinase. J. Biol. Chem. 1999, 274, 11924-11929.
33. Xu, X.P.; Meisel, S.R.; Ong, J.M.; Kaul, S.; Cercek, B.; Rajavashisth, T.B.; Sharifi, B.; Shah, P.K. Oxidized Low-Density Lipoprotein Regulates Matrix Metalloproteinase-9 and Its Tissue Inhibitor in Human Monocyte-Derived Macrophages. Circulation 1999, 99, 993-998.
34. Podrez, E.A.; Byzova, T.V.; Febbraio, M.; Salomon, R.G.; Ma, Y.; Valiyaveettil, M.; Poliakov, E.; Sun, M.; Finton, P.J.; Curtis, B.R. et al. Platelet CD36 Links Hyperlipidemia, Oxidant Stress and a Prothrombotic Phenotype. Nat. Med.2007, 13, 1086-1095.
35. Wraith, K.S.; Magwenzi, S.; Aburima, A.; Wen, Y.; Leake, D.; Naseem, M.K. Oxidized Low-Density Lipoproteins Induce Rapid Platelet Activation and Shape Change through Tyrosine Kinase and Rho Kinase-Signaling Pathways. Blood 2013, 122, 580-589.
36. Chen, M.; Kakutani, M.; Naruko, T.; Ueda, M.; Narumiya, S.; Masaki, T.; Sawamura, T. Activation-Dependent Surface Expression of LOX-1 in Human Platelets. Biochem. Biophys. Res. Commun. 2001, 282, 153-158.
37. Pirillo, A.; Norata, G.D.; Catapano, A.L. LOX-1, OxLDL, and Atherosclerosis. Mediat. Inflamm. 2013.
38. Cominacini, L.; Pasini, A.F.; Garbin, U.; Pastorino, A.; Rigoni, A.; Nava, C.; Davoli, A.; Cascio, V.L.; Sawamura, T. The Platelet-Endothelium Interaction Mediated by Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Reduces the Intracellular Concentration of Nitric Oxide in Endothelial Cells. J. Am. Coll. Cardiol. 2003, 41, 499-507.
39. Kakutani, M.; Masaki, T.; Sawamura, T. A Platelet-Endothelium Interaction Mediated by Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1. Proc. Natl. Acad. Sci. USA 2000, 97, 360-364.
40. Li, L.X.; Chen, J.X.; Liao, D.F.; Yu, L. Probucol Inhibits Oxidized-Low Density Lipoprotein-Induced Adhesion of Monocytes to Endothelial Cells by Reducing P-Selectin Synthesis in Vitro. Endothelium 1998, 6, 1-8.
41. Thorin, E.; Hamilton, C.A.; Dominiczak, M.H.; Reid, J.L. Chronic Exposure of Cultured Bovine Endothelial Cells to Oxidized LDL Abolishes Prostacyclin Release. Arterioscler. Thromb. 1994, 14, 453-459.
42. Yu, M.; Tsai, S.F.; Kuo, Y.M. The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis. Int. J. Mol. Sci. 2017, 18, 1260.
43. Uribarri, J.; Woodruff, S.; Goodman, S.; Cai, W.; Chen, X.; Pyzik, R.; Yong, A.; Striker, G.E.; Vlassara, H. Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet. J. Am. Diet. Assoc. 2010,110, 911-916.
44. Orekhov, A.N.; Bobryshev, Y.V.; Sobenin, I.A.; Melnichenko, A.A.; Chistiakov, D.A. Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease. Int. J. Mol. Sci. 2014, 15, 12807.
45. Steyers, C.; Miller, F. Endothelial Dysfunction in Chronic Inflammatory Diseases. Int. J. Mol. Sci. 2014, 15, 11324.
46. Wang, D.; Wang, Z.; Zhang, L.; Wang, Y. Roles of Cells from the Arterial Vessel Wall in Atherosclerosis. Mediat. Inflamm. 2017.
47. Napoli, C.; de Nigris, F.; Williams-Ignarro, S.; Pignalosa, O.; Sica, V.; Ignarro, L.J. Nitric Oxide and Atherosclerosis: An Update. Nitric Oxide 2006, 15, 265-279.
48. Ignarro, L.J.; Napoli, C. Novel Features of Nitric Oxide, Endothelial Nitric Oxide Synthase, and Atherosclerosis.Curr. Atheroscler. Rep. 2005, 5, 17-23.
49. Moncada, S.; Higgs, A. The L-Arginine-Nitric Oxide Pathway. N. Engl. J. Med. 1993, 329, 2002-2012.
50. Stuehr, D.J. Mammalian Nitric Oxide Synthases. Biochim. Biophys. Acta 1999, 1411, 217-230.
51. Moncada, S.; Palmer, R.M.; Higgs, E.A. Nitric Oxide: Physiology, Pathophysiology, and Pharmacology. Pharmacol. Rev. 1991, 43, 109-142.
52. Nathan, C.; Xie, Q.W. Regulation of Biosynthesis of Nitric Oxide. J. Biol. Chem. 1994, 269, 13725-13728.
53. Kawashima, S.; Mitsuhiro, Y. Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 998-1005.
54. Laursen, J.B.; Somers, M.; Kurz, S.; McCann, L.; Warnholtz, A.; Freeman, B.A.; Tarpey, M.; Fukai, T.; Harrison, D.G. Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions between Peroxynitrite and Tetrahydrobiopterin. Circulation 2001, 103, 1282-1288.
55. Lunte, C.E.; Kissinger, P.T. Determination of Quinonoid Dihydrobiopterin by Liquid Chromatography and Electrochemical Detection. J. Chromatogr. 1984, 317, 407-412.
56. Vann, L.R.; Payne, S.G.; Edsall, L.C.; Twitty, S.; Spiegel, S.; Milstien, S. Involvement of Sphingosine Kinase in TNF-α-Stimulated Tetrahydrobiopterin Biosynthesis in C6 Glioma Cells. J. Biol. Chem. 2002, 277, 12649-12656.
57. SenBanerjee, S.; Lin, Z.; Atkins, G.B.; Greif, D.M.; Rao, R.M.; Kumar, A.; Feinberg, M.W.; Chen, Z.; Simon, D.I.; Luscinskas, F.W. et al. KLF2 Is a Novel Transcriptional Regulator of Endothelial Proinflammatory Activation. J. Exp. Med. 2004, 199, 1305-1315.
58. Fan, J.; Unoki, H.; Iwasa, S.; Watanabe, T. Role of Endothelin-1 in Atherosclerosis. Ann. N. Y. Acad. Sci. 2000, 902, 84-94.
59. Pernow, J.; Shemyakin, A.; Bohm, F. New Perspectives on Endothelin-1 in Atherosclerosis and Diabetes Mellitus. Life Sci. 2012, 91, 507-516.
60. Sakurai, T.; Yanagisawa, M.; Masaki, T. Molecular Characterization of Endothelin Receptors. Trends Pharmacol. Sci.1992, 13, 103-108.
61. Schiffrin, E.L.; Touyz, R.M. Vascular Biology of Endothelin. J. Cardiovasc. Pharmacol. 1997, 32, S2-S13.
62. Yanagisawa, M.; Masaki, T. Molecular Biology and Biochemistry of the Endothelins. Trends Pharmacol. Sci. 1989,10, 374-378.
63. Böhm, F.; Pernow, J. The Importance of Endothelin-1 for Vascular Dysfunction in Cardiovascular Disease. Cardiovasc. Res. 2007, 76, 8-18.
64. Ito, H.; Hirata, Y.; Adachi, S.; Tanaka, M.; Tsujino, M.; Koike, A.; Nogami, A.; Murumo, F.; Hiroe, M. Endothelin-1 Is an Autocrine/Paracrine Factor in the Mechanism of Angiotensin II-Induced Hypertrophy in Cultured Rat Cardiomyocytes. J. Clin. Investig. 1993, 92, 398-403.
65. Iwasa, S.; Fan, J.; Shimokama, T.; Nagata, M.; Watanabe, T. Increased Immunoreactivity of Endothelin-1 and Endothelin B Receptor in Human Atherosclerotic Lesions. A Possible Role in Atherogenesis. Atherosclerosis 1999,146, 93-100.
66. Ivanova, E.A.; Orekhov, A.N. The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in Atherosclerosis. Int. J. Mol. Sci. 2016, 17, 193.
67. Filep, J.G.; Sirois, M.G.; Foldes-Filep, E.; Rousseau, A.; Plante, G.E.; Fournier, A.; Yano, M.; Sirois, P. Enhancement by Endothelin-1 of Microvascular Permeability Via the Activation of ETA Receptors. Br. J. Pharmacol. 1993, 109, 880-886.
68. Swerlick, A.R.; Lawley, T.J. Role of Microvascular Endothelial Cells in Inflammation. J. Investig. Dermatol. 1993,100, S111-S115.
69. Hansson, G.K. Inflammation, Atherosclerosis, and Coronary Artery Disease. N. Engl. J. Med. 2005, 352, 1685-1695.
70. Kume, N.; Cybulsky, M.I.; Gimbrone, M.A., Jr. Lysophosphatidylcholine, a Component of Atherogenic Lipoproteins, Induces Mononuclear Leukocyte Adhesion Molecules in Cultured Human and Rabbit Arterial Endothelial Cells. J. Clin. Investig. 1992, 90, 1138-1144.
71. Dai, G.; Kaazempur-Mofrad, M.R.; Natarajan, S.; Zhang, Y.; Vaughn, S.; Blackman, B.R.; Kamm, R.D.; Garcia-Cardena, G.; Gimbrone, M.A., Jr. Distinct Endothelial Phenotypes Evoked by Arterial Waveforms Derived from Atherosclerosis-Susceptible and -Resistant Regions of Human Vasculature. Proc. Natl. Acad. Sci. USA 2004, 101, 14871-14876.
72. Boring, L.; Gosling, J.; Cleary, M.; Charo, I.F. Decreased Lesion Formation in CCR2-/- Mice Reveals a Role for Chemokines in the Initiation of Atherosclerosis. Nature 1998, 394, 894-897.
73. Gu, L.; Okada, Y.; Clinton, S.K.; Gerard, C.; Sukhova, G.K.; Libby, P.; Rollins, B.J. Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Mice. Mol. Cell 1998, 2, 275-281.
74. Haley, K.J.; Lilly, C.M.; Yang, J.H.; Feng, Y.; Kennedy, S.P.; Turi, T.G.; Thompson, J.F.; Sukhova, G.H.; Libby, P.; Lee, R.T. Overexpression of Eotaxin and the CCR3 Receptor in Human Atherosclerosis: Using Genomic Technology to Identify a Potential Novel Pathway of Vascular Inflammation. Circulation 2000, 102, 2185-2189.
75. Mach, F.; Sauty, A.; Iarossi, A.S.; Sukhova, G.K.; Neote, K.; Libby, P.; Luster, A.D. Differential Expression of Three T Lymphocyte-Activating CXC Chemokines by Human Atheroma-Associated Cells. J. Clin. Investig. 1999, 104, 1041-1050.
76. Lesnik, P.; Haskell, C.A.; Charo, I.F. Decreased Atherosclerosis in CX3CR1-/- Mice Reveals a Role for Fractalkine in Atherogenesis. J. Clin. Investig. 2003, 111, 333-340.
77. Hansson, G.K. Immune Mechanisms in Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1876-1890.
78. Mestas, J.; Ley, K. Monocyte-Endothelial Cell Interactions in the Development of Atherosclerosis. Trends Cardiovasc. Med. 2008, 18, 228-232.
79. Moore, K.J.; Tabas, I. Macrophages in the Pathogenesis of Atherosclerosis. Cell 2011, 145, 341-355.
80. Rizzacasa, B.; Morini, E.; Pucci, S.; Murdocca, M.; Novelli, G.; Amati, F. LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies. Int. J. Mol. Sci. 2017, 18, 290.
81. Kruth, H.S. The Fate of Lipoprotein Cholesterol Entering the Arterial Wall. Curr. Opin. Lipidol. 1997, 8, 246-252.
82. Alberts-Grill, N.; Timothy, L.D.; Rezvan, A.; Jo, H. The Role of the Vascular Dendritic Cell Network in Atherosclerosis. Am. J. Phys. 2013, 305, C1-C21.
83. Hansson, G.K.; Robertson, A.K. TGF-β in Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24, e137-e138.
84. Grainger, D.J. Transforming Growth Factor β and Atherosclerosis: So Far, So Good for the Protective Cytokine Hypothesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 399-404.
85. Xu, S.; Liu, A.C.; Gotlieb, A.I. Common Pathogenic Features of Atherosclerosis and Calcific Aortic Stenosis: Role of Transforming Growth Factor-β. Cardiovasc. Pathol. 2010, 19, 236-247.
86. Grainger, D.J. TGF-β and Atherosclerosis in Man. Cardiovasc. Res. 2007, 74, 213-222.
87. McCaffrey, T.A. TGF-βs and TGF-β Receptors in Atherosclerosis. Cytokine. Growth. Factor. Rev. 2000, 11, 103-114.
88. Falck-Hansen, M.; Christina, K.; Claudia, M. Toll-Like Receptors in Atherosclerosis. Int. J. Mol. Sci. 2013, 14, 14008-14023.
89. Galkina, E.; Ley, K. Immune and Inflammatory Mechanisms of Atherosclerosis. Annu. Rev. Immunol. 2009, 27, 165-197.
90. Van Vré, E.A.; Van Brussel, I.; Bosmans, J.M.; Vrints, C.J.; Bult, H. Dendritic Cells in Human Atherosclerosis: From Circulation to Atherosclerotic Plaques. Mediat. Inflamm. 2011.
91. Aliberti, J.; Schulz, O.; Pennington, D.J.; Tsujimura, H.; e Sousa, C.R.; Ozato, K.; Sher, A. Essential Role for ICSBP in the in vivo Development of Murine CD8α+ Dendritic Cells. Blood 2003, 101, 305-310.
92. Hacker, C.; Kirsch, R.D.; Ju, X.S.; Hieronymus, T.; Gust, T.C.; Kuhl, C.; Jorgas, T.; Kurz, S.M.; Rose-John, S.; Yokota, Y. et al. Transcriptional Profiling Identifies ID2 Function in Dendritic Cell Development. Nat. Immunol.2003, 4, 380-386.
93. Hashimoto, D.; Miller, J.; Merad, M. Dendritic Cell and Macrophage Heterogeneity in vivo. Immunity 2011, 35, 323-335.
94. Hildner, K.; Edelson, B.T.; Purtha, W.E.; Diamond, M.; Matsushita, H.; Kohyama, M.; Calderon, B.; Schraml, B.U.; Unanue, E.R.; Diamond, M.S. et al. BATF3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity. Science 2008, 322, 1097-1100.
95. Schiavoni, G.; Mattei, F.; Sestili, P.; Borghi, P.; Venditti, M.; Morse, H.C.; Belardelli, F.; Gabriele, L. ICSBP Is Essential for the Development of Mouse Type I Interferon-Producing Cells and for the Generation and Activation of CD8α+ Dendritic Cells. J. Exp. Med. 2002, 196, 1415-1425.
96. Tailor, P.; Tamura, T.; Morse, H.C.; Ozato, K. The BXH2 Mutation in IRF8 Differentially Impairs Dendritic Cell Subset Development in the Mouse. Blood 2008, 111, 1942-1945.
97. Subramanian, M.; Tabas, I. Dendritic Cells in Atherosclerosis. In Semin Immunopathol; Springer: Berlin/Heidelberg, Germany, 2014; Volume 36, pp. 93-102.
98. Niessner, A.; Weyand, C.M. Dendritic Cells in Atherosclerotic Disease. Clin. Immunol. 2010, 134, 25.
99. Koltsova, E.K.; Ley, K. How Dendritic Cells Shape Atherosclerosis. Trends Immunol. 2011, 32, 540-547.
100. Zernecke, A. Dendritic Cells in Atherosclerosis: Evidence in Mice and Humans. Arterioscler. Thromb. Vasc. Biol.2015, 35, 763-770.
101. Tabas, I. Macrophage Death and Defective Inflammation Resolution in Atherosclerosis. Nat. Rev. Immunol. 2010,10, 36-46.
102. Maganto-Garcia, E.; Tarrio, M.L.; Grabie, N.; Bu, D.X.; Lichtman, A.H. Dynamic Changes in Regulatory T Cells Are Linked to Levels of Diet-Induced Hypercholesterolemia. Circulation 2011, 124, 185-195.
103. Weber, C.; Meiler, S.; Döring, Y.; Koch, M.; Drechsler, M.; Megens, R.T.; Rowinska, Z.; Bidzhekov, K.; Fecher, C.; Ribechini, E. et al. CCL17-Expressing Dendritic Cells Drive Atherosclerosis by Restraining Regulatory T Cell Homeostasis in Mice. J. Clin. Investig. 2011, 121, 2898-2910.
104. Jonasson, L.; Holm, J.; Skalli, O.; Bondjers, G.; Hansson, G.K. Regional Accumulations of T Cells, Macrophages, and Smooth Muscle Cells in the Human Atherosclerotic Plaque. Arteriosclerosis 1986, 6, 131-138.
105. Kleindienst, R.; Xu, Q.; Willeit, J.; Waldenberger, F.R.; Weimann, S.; Wick, G. Immunology of Atherosclerosis. Demonstration of Heat Shock Protein 60 Expression and T Lymphocytes Bearing α/β or γ/δ Receptor in Human Atherosclerotic Lesions. Am. J. Pathol. 1993, 142, 1927-1937.
106. Stemme, S.; Holm, J.; Hansson, G.K. T Lymphocytes in Human Atherosclerotic Plaques Are Memory Cells Expressing CD45RO and the Integrin VLA-1. Arterioscler. Thromb. 1992, 12, 206-211.
107. Van der Wal, A.C.; Das, P.K.; van de Berg, D.B.; van der Loos, C.M.; Becker, A.E. Atherosclerotic Lesions in Humans. in situ Immunophenotypic Analysis Suggesting an Immune Mediated Response. Lab. Investig. 1989, 61, 166-170.
108. Wick, G.; Jakic, B.; Buszko, M.; Wick, M.C.; Grundtman, C. The Role of Heat Shock Proteins in Atherosclerosis. Nat. Rev. Cardiol. 2014, 11, 516-529.
109. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and Atherosclerosis. Annu. Rev. Pathol. 2002, 1, 297-329.
110. Ashkar, S.; Weber, G.F.; Panoutsakopoulou, V.; Sanchirico, M.E.; Jansson, M.; Zawaideh, S.; Rittling, S.R.; Denhardt, D.T.; Glimcher, M.J.; Cantor, H. Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) Immunity. Science 2000, 287, 860-864.
111. Giachelli, C.M.; Bae, N.; Almeida, M.; Denhardt, D.T.; Alpers, C.E.; Schwartz, S.M. Osteopontin Is Elevated During Neointima Formation in Rat Arteries and Is a Novel Component of Human Atherosclerotic Plaques. J. Clin. Investig. 1993, 92, 1686-1696.
112. O’Brien, E.R.; Garvin, M.R.; Stewart, D.K.; Hinohara, T.; Simpson, J.B.; Schwartz, S.M.; Giachelli, C.M. Osteopontin Is Synthesized by Macrophage, Smooth Muscle, and Endothelial Cells in Primary and Restenotic Human Coronary Atherosclerotic Plaques. Arterioscler. Thromb. 1994, 14, 1648-1656.
113. Uyemura, K.; Demer, L.L.; Castle, S.C.; Jullien, D.; Berliner, J.A.; Gately, M.K.; Warrier, R.R.; Pham, N.; Fogelman, A.M.; Modlin, R.L. Cross-Regulatory Roles of Interleukin (IL)-12 and IL-10 in Atherosclerosis. J. Clin. Investig.1996, 97, 2130-2138.
114. Peilot, H.; Rosengren, B.; Bondjers, G.; Hurt-Camejo, E. Interferon-γ Induces Secretory Group IIA Phospholipase A2 in Human Arterial Smooth Muscle Cells. Involvement of Cell Differentiation, STAT-3 Activation, and Modulation by Other Cytokines. J. Biol. Chem. 2000, 275, 22895-22904.
115. Friesel, R.; Komoriya, A.; Maciag, T. Inhibition of Endothelial Cell Proliferation by γ-Interferon. J. Cell Biol. 1987,104, 689-696.
116. Hansson, G.K.; Hellstrand, M.; Rymo, L.; Rubbia, L.; Gabbiani, G. Interferon γ Inhibits both Proliferation and Expression of Differentiation-Specific α-Smooth Muscle Actin in Arterial Smooth Muscle Cells. J. Exp. Med. 1989,170, 1595-1608.
117. Hansson, G.K.; Holm, J. Interferon-Γ Inhibits Arterial Stenosis after Injury. Circulation 1991, 84, 1266-1272.
118. Szabo, S.J.; Sullivan, B.M.; Peng, S.L.; Glimcher, L.H. Molecular Mechanisms Regulating Th1 Immune Responses. Annu. Rev. Immunol. 2003, 21, 713-758.
119. Gewurz, H.; Zhang, X.H.; Lint, T.F. Structure and Function of the Pentraxins. Curr. Opin. Immunol. 1995, 7, 54-64.
120. Ikeda, U.; Ikeda, M.; Seino, Y.; Takahashi, M.; Kano, S.; Shimada, K. Interleukin 6 Gene Transcripts Are Expressed in Atherosclerotic Lesions of Genetically Hyperlipidemic Rabbits. Atherosclerosis 1992, 92, 213-218.
121. Loppnow, H.; Libby, P. Proliferating or Interleukin 1-Activated Human Vascular Smooth Muscle Cells Secrete Copious Interleukin 6. J. Clin. Investig. 1990, 85, 731-738.
122. Mallat, Z.; Heymes, C.; Ohan, J.; Faggin, E.; Leseche, G.; Tedgui, A. Expression of Interleukin-10 in Advanced Human Atherosclerotic Plaques: Relation to Inducible Nitric Oxide Synthase Expression and Cell Death. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 611-616.
123. Binder, C.J.; Hartvigsen, K.; Chang, M.K.; Miller, M.; Broide, D.; Palinski, W.; Curtiss, L.K.; Corr, M.; Witztum, J.L. IL-5 Links Adaptive and Natural Immunity Specific for Epitopes of Oxidized LDL and Protects from Atherosclerosis. J. Clin. Investig. 2004, 114, 427-437.
124. Shimizu, K.; Shichiri, M.; Libby, P.; Lee, R.T.; Mitchell, R.N. Th2-Predominant Inflammation and Blockade of IFN-γ Signaling Induce Aneurysms in Allografted Aortas. J. Clin. Investig. 2004, 114, 300-308.
125. Geng, Y.J.; Henderson, L.E.; Levesque, E.B.; Muszynski, M.; Libby, P. Fas Is Expressed in Human Atherosclerotic Intima and Promotes Apoptosis of Cytokine-Primed Human Vascular Smooth Muscle Cells. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2200-2208.
126. Major, A.S.; Wilson, M.T.; McCaleb, J.L.; Su, Y.R.; Stanic, A.K.; Joyce, S.; van Kaer, L.; Fazio, S.; Linton, M.F. Quantitative and Qualitative Differences in Proatherogenic NKT Cells in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 2351-2357.
127. Melian, A.; Geng, Y.J.; Sukhova, G.K.; Libby, P.; Porcelli, S.A. Cd1 Expression in Human Atherosclerosis. A Potential Mechanism for T Cell Activation by Foam Cells. Am. J. Pathol. 1999, 155, 775-786.
128. Paulsson, G.; Zhou, X.; Tornquist, E.; Hansson, G.K. Oligoclonal T Cell Expansions in Atherosclerotic Lesions of Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 10-17.
129. Tupin, E.; Nicoletti, A.; Elhage, R.; Rudling, M.; Ljunggren, H.G.; Hansson, G.K.; Berne, G.P. CD1D-Dependent Activation of NKT Cells Aggravates Atherosclerosis. J. Exp. Med. 2004, 199, 417-422.
130. Bot, I.; de Jager, S.C.; Zernecke, A.; Lindstedt, K.A.; van Berkel, T.J.; Weber, C.; Biessen, E.A. Perivascular Mast Cells Promote Atherogenesis and Induce Plaque Destabilization in Apolipoprotein E-Deficient Mice. Circulation2007, 115, 2516-2525.
131. Lindstedt, K.A.; Mäyränpää, M.I.; Kovanen, P.T. Mast Cells in Vulnerable Atherosclerotic Plaques-A View to a Kill. J. Cell Mol. Med. 2007, 11, 739-758.
132. Lee, M.; Calabresi, L.; Chiesa, G.; Franceschini, G.; Kovanen, P.T. Mast Cell Chymase Degrades ApoE and ApoA-II in ApoA-I-Knockout Mouse Plasma and Reduces Its Ability to Promote Cellular Cholesterol Efflux. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1475-1481.
133. Sun, J.; Sukhova, G.K.; Wolters, P.J.; Yang, M.; Kitamoto, S.; Libby, P.; MacFarlane, L.A.; Clair, J.M.; Shi, G.P. Mast Cells Promote Atherosclerosis by Releasing Proinflammatory Cytokines. Nat. Med. 2007, 13, 719-724.
134. Binder, C.J.; Shaw, P.X.; Chang, M.K.; Boullier, A.; Hartvigsen, K.; Horkko, S.; Miller, Y.I.; Woelkers, D.A.; Corr, M.; Witztum, J.L. The Role of Natural Antibodies in Atherogenesis. J. Lipid Res. 2005, 46, 1353-1363.
135. Caligiuri, G.; Nicoletti, A.; Poirier, B.; Hansson, G.K. Protective Immunity against Atherosclerosis Carried by B Cells of Hypercholesterolemic Mice. J. Clin. Investig. 2002, 109, 745-753.
136. Major, A.S.; Fazio, S.; Linton, M.F. B-Lymphocyte Deficiency Increases Atherosclerosis in LDL Receptor-Null Mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1892-1898.
137. Shaw, P.X.; Horkko, S.; Chang, M.K.; Curtiss, L.K.; Palinski, W.; Silverman, G.J.; Witztum, J.L. Natural Antibodies with the T15 Idiotype May Act in Atherosclerosis, Apoptotic Clearance, and Protective Immunity. J. Clin. Investig.2000, 105, 1731-1740.
138. Schulz, C.; Massberg, S. Platelets in Atherosclerosis and Thrombosis. Handb. Exp. Pharmacol. 2012, 111-133.
139. Lievens, D.; von Hundelshausen, P. Platelets in Atherosclerosis. Thromb. Haemost. 2011, 106, 827-838.
140. Huo, Y.; Ley, K.F. Role of Platelets in the Development of Atherosclerosis. Trends Cardiovasc. Med. 2004, 14, 18-22.
141. Badimon, L.; Padró, T.; Vilahur, G. Atherosclerosis, Platelets and Thrombosis in Acute Ischaemic Heart Disease. Eur. Heart J. Acute Cardiovasc. Care 2012, 1, 60-74.
142. Koltai, K.; Kesmarky, G.; Feher, G.; Tibold, A.; Toth, K. Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. Int. J. Mol. Sci. 2017, 18, 1803.
143. Andrews, R.K.; Berndt, M.C. Platelet Physiology and Thrombosis. Thromb. Res. 2004, 114, 447-453.
144. Ruggeri, Z.M.; Bader, R.; de Marco, L. Glanzmann Thrombasthenia: Deficient Binding of Von Willebrand Factor to Thrombin-Stimulated Platelets. Proc. Natl. Acad. Sci. USA 1982, 79, 6038-6041.
145. Ni, H.; Denis, C.V.; Subbarao, S.; Degen, J.L.; Sato, T.N.; Hynes, R.O.; Wagner, D.D. Persistence of Platelet Thrombus Formation in Arterioles of Mice Lacking Both Von Willebrand Factor and Fibrinogen. J. Clin. Investig.2000, 106, 385-392.
146. Hantgan, R.R. Fibrin Protofibril and Fibrinogen Binding to ADP-Stimulated Platelets: Evidence for a Common Mechanism. Biochim. Biophys. Acta 1988, 968, 24-35.
147. Bennett, J.S.; Vilaire, G. Exposure of Platelet Fibrinogen Receptors by ADP and Epinephrine. J. Clin. Investig. 1979,64, 1393-1401.
148. Das, U.N. Atherosclerosis and Prostaglandins. Int. J. Tissue React. 1982, 4, 127-132.
149. Martínez-Sánchez, S.M.; Minguela, A.; Prieto-Merino, D.; Zafrilla-Rentero, M.P.; Abellán-Alemán, J.; Montoro-García, S. The Effect of Regular Intake of Dry-Cured Ham Rich in Bioactive Peptides on Inflammation, Platelet and Monocyte Activation Markers in Humans. Nutrients 2017, 9, 321.
150. Molica, F.; Stierlin, F.B.; Fontana, P.; Kwak, B.R. Pannexin- and Connexin-Mediated Intercellular Communication in Platelet Function. Int. J. Mol. Sci. 2017, 18, 850.
151. Virmani, R.; Burke, A.P.; Farb, A. Plaque Rupture and Plaque Erosion. Thromb. Haemost. 1999, 82, 1-3.
152. Lafont, A. Basic Aspects of Plaque Vulnerability. Heart 2003, 89, 1262-1267.
153. Hansson, G.K.; Libby, P.; Tabas, I. Inflammation and Plaque Vulnerability. J. Int. Med. 2015, 278, 483-493.
154. Shah, P.K. Mechanisms of Plaque Vulnerability and Rupture. J. Am. Coll. Cardiol. 2003, 41, S15-S22.